Matches in SemOpenAlex for { <https://semopenalex.org/work/W1119150976> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W1119150976 endingPage "610" @default.
- W1119150976 startingPage "605" @default.
- W1119150976 abstract "The azacitidine (Vidaza®) product monograph indicates that doses greater than 4 ml should be divided equally into two syringes and injected into different sites. Although 2 ml is a more commonly used maximum volume for subcutaneous injections, there is a lack of evidence to support the use of any given maximum volume with azacitidine. Applying the status quo of 2 ml to azacitidine results in patients receiving 3–4 injections per visit. This prospective study evaluated the frequency and type of injection site reactions when the maximum subcutaneous injection volume was increased from 2 to 3 ml per injection site. Among 30 patients, 309 doses were administered, and injection site reactions were noted in 92.9% of all doses, with the majority (82.2%) being grade 1; only 10.7% of doses resulted in grade 2 reactions, and there were no grade 3 or 4 reactions. There was no increase in frequency or severity of injection site reactions when the maximum volume was increased to 3 ml. The median number of injections that patients received per visit decreased from 3 to 2 after the volume was increased, and there was a statistically significant reduction in the incidence of pain. Decreasing the number of injections also facilitates ease of rotation of injection sites and decreases pharmacy preparation time. This is the first time that injection site reaction data relating to injection volume have been reported for azacitidine." @default.
- W1119150976 created "2016-06-24" @default.
- W1119150976 creator A5007848676 @default.
- W1119150976 creator A5015365868 @default.
- W1119150976 creator A5015762657 @default.
- W1119150976 creator A5018846982 @default.
- W1119150976 creator A5033052612 @default.
- W1119150976 creator A5055906478 @default.
- W1119150976 creator A5076718701 @default.
- W1119150976 date "2015-08-05" @default.
- W1119150976 modified "2023-09-24" @default.
- W1119150976 title "Tolerability of Vidaza (azacitidine) subcutaneous administration using a maximum volume of 3 ml per injection" @default.
- W1119150976 cites W1988907854 @default.
- W1119150976 cites W2005969440 @default.
- W1119150976 cites W2018796671 @default.
- W1119150976 cites W2060311019 @default.
- W1119150976 cites W2061711005 @default.
- W1119150976 cites W2148428508 @default.
- W1119150976 cites W2163972237 @default.
- W1119150976 doi "https://doi.org/10.1177/1078155215598854" @default.
- W1119150976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26248754" @default.
- W1119150976 hasPublicationYear "2015" @default.
- W1119150976 type Work @default.
- W1119150976 sameAs 1119150976 @default.
- W1119150976 citedByCount "5" @default.
- W1119150976 countsByYear W11191509762016 @default.
- W1119150976 countsByYear W11191509762020 @default.
- W1119150976 countsByYear W11191509762021 @default.
- W1119150976 countsByYear W11191509762023 @default.
- W1119150976 crossrefType "journal-article" @default.
- W1119150976 hasAuthorship W1119150976A5007848676 @default.
- W1119150976 hasAuthorship W1119150976A5015365868 @default.
- W1119150976 hasAuthorship W1119150976A5015762657 @default.
- W1119150976 hasAuthorship W1119150976A5018846982 @default.
- W1119150976 hasAuthorship W1119150976A5033052612 @default.
- W1119150976 hasAuthorship W1119150976A5055906478 @default.
- W1119150976 hasAuthorship W1119150976A5076718701 @default.
- W1119150976 hasConcept C104317684 @default.
- W1119150976 hasConcept C126322002 @default.
- W1119150976 hasConcept C150194340 @default.
- W1119150976 hasConcept C185592680 @default.
- W1119150976 hasConcept C190727270 @default.
- W1119150976 hasConcept C197934379 @default.
- W1119150976 hasConcept C2776239401 @default.
- W1119150976 hasConcept C2776390293 @default.
- W1119150976 hasConcept C2778375690 @default.
- W1119150976 hasConcept C3018125106 @default.
- W1119150976 hasConcept C42219234 @default.
- W1119150976 hasConcept C55493867 @default.
- W1119150976 hasConcept C71924100 @default.
- W1119150976 hasConceptScore W1119150976C104317684 @default.
- W1119150976 hasConceptScore W1119150976C126322002 @default.
- W1119150976 hasConceptScore W1119150976C150194340 @default.
- W1119150976 hasConceptScore W1119150976C185592680 @default.
- W1119150976 hasConceptScore W1119150976C190727270 @default.
- W1119150976 hasConceptScore W1119150976C197934379 @default.
- W1119150976 hasConceptScore W1119150976C2776239401 @default.
- W1119150976 hasConceptScore W1119150976C2776390293 @default.
- W1119150976 hasConceptScore W1119150976C2778375690 @default.
- W1119150976 hasConceptScore W1119150976C3018125106 @default.
- W1119150976 hasConceptScore W1119150976C42219234 @default.
- W1119150976 hasConceptScore W1119150976C55493867 @default.
- W1119150976 hasConceptScore W1119150976C71924100 @default.
- W1119150976 hasIssue "4" @default.
- W1119150976 hasLocation W11191509761 @default.
- W1119150976 hasLocation W11191509762 @default.
- W1119150976 hasOpenAccess W1119150976 @default.
- W1119150976 hasPrimaryLocation W11191509761 @default.
- W1119150976 hasRelatedWork W1119150976 @default.
- W1119150976 hasRelatedWork W1991018525 @default.
- W1119150976 hasRelatedWork W2005969440 @default.
- W1119150976 hasRelatedWork W2076974583 @default.
- W1119150976 hasRelatedWork W2549972050 @default.
- W1119150976 hasRelatedWork W2564087971 @default.
- W1119150976 hasRelatedWork W2754690855 @default.
- W1119150976 hasRelatedWork W2952979093 @default.
- W1119150976 hasRelatedWork W4283312868 @default.
- W1119150976 hasRelatedWork W4292682120 @default.
- W1119150976 hasVolume "22" @default.
- W1119150976 isParatext "false" @default.
- W1119150976 isRetracted "false" @default.
- W1119150976 magId "1119150976" @default.
- W1119150976 workType "article" @default.